KR101729239B1 - Synthetic method for moracin F using intramolecular Wittig reaction - Google Patents
Synthetic method for moracin F using intramolecular Wittig reaction Download PDFInfo
- Publication number
- KR101729239B1 KR101729239B1 KR1020160035653A KR20160035653A KR101729239B1 KR 101729239 B1 KR101729239 B1 KR 101729239B1 KR 1020160035653 A KR1020160035653 A KR 1020160035653A KR 20160035653 A KR20160035653 A KR 20160035653A KR 101729239 B1 KR101729239 B1 KR 101729239B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- mmol
- formula
- bis
- nmr
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Agronomy & Crop Science (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pest Control & Pesticides (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 천연 벤조퓨란 화합물인 모라신 F를 합성하는 방법에 관한 것으로서, 좀 더 자세히는 분자내 위티그 반응을 핵심 단계로 하여 모라신 F를 합성하는 방법에 관한 것이다.The present invention relates to a method for synthesizing morazin F, which is a natural benzofuran compound, and more particularly, to a method for synthesizing morazin F with intramolecular Wittig reaction as a key step.
헤테로사이클릭 화합물은 현존하는 유기 화합물의 절반 이상을 차지하며 의화학 및 약품 발견에서 중요한 역할을 수행할 수 있다. 융합된 헤테로사이클릭 화합물인 벤조퓨란은 수많은 천연 산물에 존재하며 의학적 및 생물학적 중요성의 관점에서 볼 때 식물 페놀 중 두드러진 위치를 차지한다 [1]. 특히, 몇몇 천연 및 비천연 2-치환 벤조퓨란은 항염증, 항산화, 항암, 항진균, 항미생물, 항혈소판 및 항바이러스 활성을 포함하여 중요한 생물학적 특성을 나타낸다 [2~8]. 또한, 어떤 유도체들은 효소 억제제 [9]로서, 그리고 알츠하이머 병에서 아밀로이드반 (amyloid plaques)을 표적으로 하는 진단 이미지 제제 [10]로서 연구되고 있다. 어떤 벤조퓨란 화합물들은 유기 반도체 분야에서 연구되고 있다 [11]. 또한, 이 화합물들은 증백제 (brightening agent) [12]로서, 그리고 농업 분야에서 농약과 살충제 [13]로 적용 가능성을 찾고 있다.Heterocyclic compounds occupy more than half of the existing organic compounds and can play an important role in the chemical and drug discovery. The fused heterocyclic compound, benzofuran, is present in numerous natural products and occupies a prominent position among plant phenols in terms of medical and biological importance [1]. In particular, some natural and non-natural 2-substituted benzofurans exhibit important biological properties including anti-inflammatory, antioxidant, anticancer, antifungal, antimicrobial, antiplatelet and antiviral activity [2-8]. In addition, some derivatives have been studied as enzyme inhibitors [9] and as diagnostic imaging agents targeting amyloid plaques in Alzheimer's disease [10]. Some benzofuran compounds have been studied in the field of organic semiconductors [11]. In addition, these compounds are looking for applicability as brightening agents [12] and in agriculture as pesticides and pesticides [13].
모러스 (Morus) 속은 화훼류인 모라세아에 (Moraceae)에 속하며 세계적으로 널리 분포하는 약 16종을 포함한다. 모러스 속은 의약적 가치와 경제적 가치로 인해 상당한 관심을 받고 있다 [14]. 최근의 리뷰에서, Naik 등은 모러스 속으로부터 벤조퓨란 (모라신 A-Z)의 분리를 강조하였으며, 구조체 골격을 구축하는데 이용하는 서로 다른 합성방법을 정리하였다 [15]. 모라신 F (도 1)는 F. solani f. sp . mori로 감염된 뽕나무 싹의 껍질 및 체관부 조직의 아세톤 추출물에서 분리되었고 [16], 그 합성에 관해서는 보고된 바 없다.The genus Morus belongs to the flowering family Moraceae and contains about 16 species that are widely distributed throughout the world. The genus Morus has received considerable attention due to its medicinal and economic value [14]. In a recent review, Naik et al. Emphasized the separation of benzofuran (morazin AZ) from the genus Morus, and summarized the different synthetic methods used to construct the structural framework [15]. Mora Shin F (Fig. 1) F. solani f. sp . mori , and the acetone extract of tubal tissues [16], but no synthesis has been reported.
본 발명은 위와 같이 생물학적 활성을 가진 천연 화합물 모라신 F를 합성하는 방법을 제공하는 것을 목표로 한다.The present invention aims to provide a method for synthesizing a natural compound morasin F having biological activity as described above.
항염증제로서 벤조퓨란 [17]의 합성 및 생물학적 평가에 대한 관심을 지속하면서, 본 발명자들은 천연 벤조퓨란인 모라신 F를 소노가시라 커플링 반응 (Sonogashira coupling), 스즈키 커플링 반응 (Suzuki coupling), Al2O3 매개 원환화 및 분자내 위티그 반응을 주요 단계로 이용하는 다양한 방법으로 합성하는 방법을 발명하였다.As a result of continuing interest in the synthesis and biological evaluation of benzofuran [17] as an anti-inflammatory agent, the present inventors have succeeded in synthesizing morphine F, which is natural benzofuran, by Sonogashira coupling, Suzuki coupling, 2 O 3 mediated cyclization and intramolecular Wittig reaction as main steps.
핵심 반응으로서 소노가시라 커플링 반응 [17a]을 이용하여 화합물 1을 합성하는 방법은 TBDMS-Cl (tert-butyldimethylsilyl chloride)를 이용하여 3,4-다이메톡시페놀 (화합물 2)을 보호기화하는 것으로 시작한다 (도 2). I2/AgSO4 시스템을 이용한 화합물 3의 위치선택적 요오드화는 TBS가 없는 요오드 화합물 4를 제공한다. 3,5-다이하이드록시벤즈알데하이드 (화합물 5)는 K2CO3 존재하에서 EOM-Cl (chloromethyl ethyl ether)로 처리하였고 그 결과 얻어진 EOM기로 보호되는 알데하이드 화합물은 콜빈 재배열 [18]에 의해 동족의 알킨으로 전환되었다. 다음으로, 화합물 4와 화합물 7 간의 소노가시라 커플링으로 EOM기로 보호되는 벤조퓨란 화합물 8이 생성되었는데, 이것을 Dowex® 수지로 처리하여 목표 화합물인 모라신 F (화합물 1)를 얻었다.As a key reaction,
다음으로, 중성 Al2O3 매개 원환화를 주요 단계 [17c]로 이용하는 모라신 F의 합성은 3,5-다이하이드록시아세토페논 (화합물 9)의 TBS-보호기화로 시작하였다 (도 3). 얻어진 화합물 10은 브롬화구리 (copper bromide; CuBr2)를 이용하여 해당 페나실 브로마이드 화합물 11로 전환되었다. Next, the synthesis of morasin F using the neutral Al 2 O 3 mediated cyclization as the main step [17c] began with the TBS-protection of 3,5-dihydroxyacetophenone (compound 9) (FIG. 3).
화합물 11로 화합물 2를 위치선택적 원환화하는 것은 중성 Al2O3를 가하여 용이해졌으며, 그리하여 TBS로 보호되는 벤조퓨란 화합물 12가 생성되는데, 이것을 1.0M TBAF (tetrabutylammonium fluoride) (THF 용액)으로 처리하여 화합물 1을 높은 수율로 얻었다. Positively selective cyclization of
천연 벤조퓨란 화합물 1의 합성은 또한 도 4에 개시된 다른 접근법으로도 가능하였다. 벤조퓨란 골격 형성에서 핵심 단계는 트리페닐포스포늄염 화합물 18과 3,5-비스(알릴옥시)벤조일클로라이드 화합물 15 간의 분자 내 위티그 반응으로 달성되었다 (도 4). 바람직한 위티그 시약 화합물 18은 PPh3.HBr (triphenylphosphine hydrobromide)과 벤질 알콜 화합물 17로부터 제조되었으며, 화합물 17은 해당 알데하이드 화합물을 환원하여 얻어진 것이다. 염화산 (acid chloride) 화합물 15는 3,5-다이하이드록시벤조산 화합물 13을 알릴 보호기화-에스테르화, 에스테르 가수분해 및 염소화와 같은 순서에 따라 반응시켜 제조하였다. 위티그 반응으로 알릴기로 보호된 벤조퓨란 화합물 19가 생성되며, 이것에 K2CO3 및 촉매 Pd(PPh3)4를 가하여 86% 수율로 목표 화합물 1을 얻었다.The synthesis of
최종적으로 본 발명자들은 화합물 1 합성에 스즈키 커플링 방법 [17d]을 이용할 수 있음을 확인하였다. 이 방법은 알데하이드 화합물 16의 라미레즈 젬-다이브로모올레핀화 반응으로 시작하였다 (도 5). 이 반응으로 얻은 젬-다이브로모올레핀 화합물 20은 무수 K3PO4/CuI 시스템을 이용한 분자내 교차 커플링으로 2-브로모벤조퓨란 화합물 21을 생성하였다. 해당 보론 에스테르 커플링 시약 23은 시판하는 5-브로모에소르시놀 (5-bromoresorcinol) 화합물 22로부터 얻었다 [17b]. 밀봉된 튜브 안에서 Pd(PPh3)4 (10 mmol%)와 염기로서 수용성 2.0 M K2CO3 용액 및 용매로서 THF를 이용하여 100℃에서 화합물 21과 화합물 23 간의 스즈키 커플링을 수행하여 벤조퓨란 화합물을 수율 10%로 얻었다. 다음으로, 밀봉된 튜브 안에서 DMF (N,N-dimethylformamide) 용매 내에서 PdCl2(dppf).CH2Cl2 (5 mmol%)와 염기로서 무수 K3PO4를 가하여 120℃에서 반응시켜 벤조퓨란 화합물 8을 35% 수율로 얻었으며, 화합물 8로부터 도 1과 같이 화합물 1을 얻었다.Finally, the present inventors confirmed that the Suzuki coupling method [17d] can be used for the synthesis of
결론적으로, 본 발명자들은 주요 단계로서 스즈키 커플링, 소노가시라 커플링, 중성 Al2O3 매개 원환화 및 세포내 위티그 반응을 채용하는 네 가지 다른 접근방법을 이용하여 천연 2-아릴벤조퓨란 화합물인 모라신 F (moracin F) 를 합성하였다. 모든 접근방법은 상업적으로 입수 가능한 출발물질로부터 시작하였고 다른 접근법에 비해 스즈키 커플링 접근방법이 실행 가능한 가장 효율적인 방법임을 알게 되었다.In conclusion, the present inventors have used four different approaches employing Suzuki coupling, Sonogashira coupling, neutral Al 2 O 3 mediated cyclization and intracellular Wittig reaction as key steps to synthesize natural 2-arylbenzofuran compounds Morosa F (moracin F) was synthesized. All approaches have started with commercially available starting materials and have found that the Suzuki coupling approach is the most viable and feasible way of approaching other approaches.
본 발명은The present invention
(가) 화학식 18로 표시되는 2-((브로모트리페닐포스포라닐)메틸)-4,5-다이메톡시페놀 {2-((Bromotriphenylphosphoranyl)methyl)-4,5-dimethoxyphenol}과 화학식 15로 표시되는 3,5-비스(알릴옥시)벤조일클로라이드 간의 분자 내 위티그 반응으로 화학식 19로 표시되는 2-(3,5-비스(알릴옥시)페닐)-5,6-다이메톡시벤조퓨란 {2-(3,5-Bis(allyloxy)phenyl)-5,6-dimethoxybenzofuran}을 얻는 단계; 및(A) 2 - ((Bromotriphenylphosphoranyl) methyl) -4,5-dimethoxyphenol represented by the formula (18) and {2 - ((Bromotriphenylphosphoranyl) methyl) (Allyloxy) phenyl) -5,6-dimethoxybenzoyl chloride represented by the
(나) 상기 2-(3,5-비스(알릴옥시)페닐)-5,6-다이메톡시벤조퓨란에 K2CO3 및 촉매 Pd(PPh3)4를 가하여 모라신 F를 얻는 단계;를 포함하는 모라신 F 합성방법에 관한 것이다.(B) adding K 2 CO 3 and catalyst Pd (PPh 3 ) 4 to the 2- (3,5-bis (allyloxy) phenyl) -5,6-dimethoxybenzofuran to obtain morasin F; To a morphine F synthesis method.
<화학식 18>≪
<화학식 15>≪
<화학식 19>(19)
또한, 본 발명은 상기 3,5-비스(알릴옥시)벤조일클로라이드가 3,5-다이하이드록시벤조산을 알릴 보호기화-에스테르화, 에스테르 가수분해 및 염소화의 순서에 따라 반응시켜 제조한 것임을 특징으로 하는 모라신 F 합성방법에 관한 것이다.Further, the present invention is characterized in that the 3,5-bis (allyloxy) benzoyl chloride is prepared by reacting 3,5-dihydroxybenzoic acid with allyl protecting group-esterifying, ester hydrolysis and chlorination in the order To a morphine F synthesis method.
또한, 본 발명은 상기 2-((브로모트리페닐포스포라닐)메틸)-4,5-다이메톡시페놀은 (ㄱ) 화학식 16으로 표시되는 2-하이드록시-4,5-다이메톡시벤즈알데하이드를 환원시켜 화학식 17로 표시되는 2-(하이드록시메틸)-4,5-다이메톡시페놀 {2-(Hydroxymethyl)-4,5-dimethoxyphenol}을 얻는 단계; 및In addition, the present invention relates to a process for preparing 2 - ((bromotriphenylphosphoranyl) methyl) -4,5-dimethoxyphenol by reacting 2-hydroxy-4,5-dimethoxy Benzaldehyde is reduced to obtain 2- (hydroxymethyl) -4,5-dimethoxyphenol {2- (Hydroxymethyl) -4,5-dimethoxyphenol} represented by
(ㄴ) 상기 2-(하이드록시메틸)-4,5-다이메톡시페놀을 PPh3·HBr (triphenylphosphinehydrobromide)와 반응시켜 2-((브로모트리페닐포스포라닐)메틸)-4,5-다이메톡시페놀을 얻는 단계;를 포함하는 모라신 F 합성방법에 관한 것이다. (B) reacting the 2- (hydroxymethyl) -4,5-dimethoxyphenol with PPh 3揃 HBr (triphenylphosphinehydrobromide) to obtain 2 - ((bromotriphenylphosphoranyl) methyl) To obtain a dimethoxy phenol.
<화학식 16>≪
<화학식 17>≪
본 발명에 따르면, 상업적으로 입수 가능한 출발물질로부터 분자내 위티그 반응을 이용하여 생물학적 활성을 가진 모라신 F를 효율적으로 합성할 수 있다.According to the present invention, morasin F having biological activity can be efficiently synthesized by using an intramolecular Wittig reaction from a commercially available starting material.
도 1은 모라신 F의 화학구조식이다.
도 2는 소노가시라 커플링 반응을 핵심 단계로 하는 모라신 F 합성방법의 일 실시예를 도시한 화학반응식이다.
도 3은 Al2O3 매개 원환화를 핵심 단계로 하는 모라신 F 합성방법의 일 실시예를 도시한 화학반응식이다.
도 4는 세포내 위티그 반응을 핵심 단계로 하는 모라신 F 합성방법의 일 실시예를 도시한 화학반응식이다.
도 5는 스즈키 커플링 반응을 핵심 단계로 하는 모라신 F 합성방법의 일 실시예를 도시한 화학반응식이다.1 is a chemical structural formula of morphine F. Fig.
FIG. 2 is a chemical reaction formula showing one embodiment of morasin F synthesis method in which Sonogashira coupling reaction is a key step.
FIG. 3 is a chemical reaction formula showing an embodiment of the morasin F synthesis method in which the Al 2 O 3 mediator ring is a key step.
FIG. 4 is a chemical reaction formula showing one embodiment of morphine F synthesis method in which intracellular Wistig reaction is a key step.
5 is a chemical reaction formula showing one embodiment of morphine F synthesis method with Suzuki coupling reaction being a key step.
아래에서는 구체적인 실시예를 들어 본 발명의 구성을 좀 더 자세히 설명한다. 그러나, 본 발명의 범위가 실시예의 기재에만 한정된 것이 아님은 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 자명하다.Hereinafter, the configuration of the present invention will be described in more detail with reference to specific embodiments. However, it is apparent to those skilled in the art that the scope of the present invention is not limited to the description of the embodiments.
모든 화학제품은 특별한 언급이 없는 한 구입한 그대로 정제하지 않고 사용하였다. 반응에 사용된 모든 용매는 질소 가스 하에서 적절한 탈수제로 증류하였다. 크로마토그래피에 사용한 모든 용매는 구입하여 별도의 정제 없이 바로 사용하였다. 1H-NMR 스펙트럼은 Varian Mercury에 300 MHz FT-NMR 및 13C에 대해서는 75 MHz로 기록하였고, 화학적 이동 (δ)은 TMS에 대하여 ppm (parts per million)으로 나타내었고, CDCl3/CD3OD/CD3COCD3는 용매 및 내부 스탠다드로 이용하였다. 질량 스펙트럼은 Agilent-5977E spectrometer를 이용하여 기록하였다. 녹는점은 MEL-TEMP Ⅱ 장치에서 측정하고, 보정하지 않았다. 박막 크로마토그래피 (TLC)는 DC-Plastikfolien 60, F254 (Merck, 층 두께 0.2 mm) 플라스틱 판에 실리카젤을 입힌 플레이트를 이용하였고, UV (254 nm)를 이용하여 관찰하거나 또는 p-아니스알데하이드와 포스포몰리브딕산 (PMA)으로 염색하여 관찰하였다. 크로마토그래피 정제는 Kieselgel 60 (60-120 mesh, Merck)을 이용하여 수행하였다.All chemicals were used without purification as purchased unless otherwise noted. All the solvents used in the reaction were distilled under a nitrogen gas with an appropriate dehydrating agent. All solvents used in the chromatography were purchased and immediately used without further purification. The 1 H-NMR spectra were recorded on a Varian Mercury at 300 MHz FT-NMR and 13 C at 75 MHz, chemical shifts (δ) were expressed in parts per million (ppm) relative to TMS, and CDCl 3 / CD 3 OD / CD 3 COCD 3 was used as a solvent and an internal standard. Mass spectra were recorded using an Agilent-5977E spectrometer. Melting points were measured on the MEL-TEMP II apparatus and not calibrated. Thin-film chromatography (TLC) was performed on plates coated with silica gel on a DC-Plasticfolien 60, F 254 (Merck, 0.2 mm thick) plastic plate and observed with UV (254 nm) or with p- anisaldehyde And stained with phosphomolybdic acid (PMA). Chromatographic purification was performed using Kieselgel 60 (60-120 mesh, Merck).
terttert -- 부틸(3,4-다이메톡시페녹시)다이메틸실란Butyl (3,4-dimethoxyphenoxy) dimethylsilane { { terttert -Butyl(3,4-dimethoxyphenoxy)dimethylsilane} (화합물 3) -Butyl (3,4-dimethoxyphenoxy) dimethylsilane} (Compound 3)
무수 DMF (1.5 mL) 내의 TBSCl (0.294 g, 1.95 mmol)에 3,4-다이메톡시페놀 (화합물 2) (0.2 g, 1.30 mmol)과 이미다졸 (0.221 g, 3.25 mmol)을 무수 DMF (6 mL)에 넣고 교반한 용액을 가하였다. 반응 혼합물은 40℃에서 네 시간 동안 교반하였다. 반응 완료 후, 에테르 (20 mL)로 희석하고, 물 (3 × 25 mL), 식염수 (3 × 25 mL)로 씻은 후, 무수 Na2SO4로 건조하고 진공농축하였다. 조화합물은 컬럼 크로마토그래피 (EtOAC/Hexane=1/15)로 정제하여 무색 액체인 순수한 화합물 3 (0.33g, 94%)을 얻었다. Rf= 0.48 (EtOAc/hexane=1/15); 1H NMR (300 MHz, CDCl3) δ 6.70 (1H, d, J = 8.1 Hz), 6.41 (1H, d, J = 2.4 Hz), 6.35 (1H, dd, J = 8.1, 2.4 Hz), 3.83 (3H, s), 3.82 (3H, s), 0.98 (9H, s), 0.18 (6H, s); 13C NMR (75 MHz, CDCl3) δ 149.6, 149.3, 143.5, 111.6, 110.5, 104.8, 56.3, 55.8, 25.8, 18.3, -4.33,4-dimethoxyphenol (Compound 2 ) (0.2 g, 1.30 mmol) and imidazole (0.221 g, 3.25 mmol) were dissolved in anhydrous DMF (6 ml) mL) and the stirred solution was added. The reaction mixture was stirred at 40 < 0 > C for four hours. After completion of the reaction, it was diluted with ether (20 mL), washed with water (3 x 25 mL), brine (3 x 25 mL), dried over anhydrous Na 2 SO 4 and concentrated in vacuo. The crude compound was purified by column chromatography (EtOAC / Hexane = 1/15) to obtain pure compound 3 (0.33 g, 94%) as a colorless liquid. Rf = 0.48 (EtOAc / hexane = 1/15); 1 H NMR (300 MHz, CDCl 3) δ 6.70 (1H, d, J = 8.1 Hz), 6.41 (1H, d, J = 2.4 Hz), 6.35 (1H, dd, J = 8.1, 2.4 Hz), 3.83 (3H, s), 3.82 (3H, s), 0.98 (9H, s), 0.18 (6H, s); 13 C NMR (75 MHz, CDCl 3 ) 隆 149.6, 149.3, 143.5, 111.6, 110.5, 104.8, 56.3, 55.8, 25.8, 18.3,
2-2- 아이오도Iodo -4,5--4,5- 다이메톡시페놀Dimethoxyphenol (2- (2- IodoIodo -4,5--4,5- dimethoxyphenoldimethoxyphenol ) (화합물 4)) (Compound 4)
화합물 3 (0.2 g, 0.76 mmol)을 에탄올 (6 mL)에 넣고 교반한 용액에 분자 요오드 (0.208 g, 0.84 mmol)와 황산은 (0.236 g, 0.84 mmol)을 가하였다. 반응 혼합액은 상온에서 48시간 동안 교반하였다. 반응 완료 후 포화 티오황산나트륨 (sodium thiosulphate) 용액으로 희석하고 에탄올 용매를 진공에서 제거하였다. 화합물은 EtOAc (2 x 25 mL)로 추출하였다. 혼합 유기용매층은 식염수 (2 x 30 mL)로 씻고, 무수 Na2SO4로 건조하고 진공농축하였다. 조화합물은 컬럼 크로마토그래피 (EtOAC/Hexane=1/6)로 정제하여 갈색 액체인 순수한 화합물 4를 얻었다. Rf= 0.28 (EtOAc/hexane=1/2); 1H NMR (300 MHz, CDCl3) δ 7.02 (1H, s), 6.59 (1H, s), 5.25 (1H, s), 3.84 (3H, s), 3.80 (6H, s); 13C NMR (75 MHz, CDCl3) δ 151.0, 149.8, 144.1, 119.9, 99.6, 71.8, 56.9, 56.3.Molecular iodine (0.208 g, 0.84 mmol) and sulfuric acid silver (0.236 g, 0.84 mmol) were added to a stirred solution of compound 3 (0.2 g, 0.76 mmol) in ethanol (6 mL). The reaction mixture was stirred at room temperature for 48 hours. After completion of the reaction, the reaction mixture was diluted with a saturated sodium thiosulfate solution and the ethanol solvent was removed in vacuo. The compound was extracted with EtOAc (2 x 25 mL). Mixing the organic solvent layer is washed with brine (2 x 30 mL), dried over anhydrous Na 2 SO 4, and concentrated in vacuo. The crude compound was purified by column chromatography (EtOAC / Hexane = 1/6) to obtain
3,5-3,5- 비스(에톡시메톡시)벤즈알데하이드Bis (ethoxymethoxy) benzaldehyde {3,5- {3,5- BisBis (( ethoxymethoxyethoxyMethane )- benzaldehyde} (화합물 6) ) -benzaldehyde < / RTI > (Compound 6)
3,5-다이하이드록시벤즈알데하이드 (0.138 g, 1.0 mmol)를 무수 DMF (7 mL)에 넣고 교반한 용액에 질소 분위기 하 상온에서 K2CO3 (0.553 g, 4.0 mmol)를 가하였다. 15분 동안 교반한 다음, 클로로메틸에틸에테르 (0.28 mL, 3.0 mmol)를 한 방울씩 가하고 상온에서 밤새 교반하였다. 반응 완료 후 물 (10 mL)로 희석하고 에테르 (3 x 30 mL)로 추출하였다. 혼합 유기용매층은 물 (3 x 30 mL)과 식염수 (3 x 30 mL)로 연이어 씻고, 무수 Na2SO4로 건조하고 진공농축하였다. 조화합물은 컬럼 크로마토그래피 (EtOAc/hexane=1/6)로 정제하여 무색 액체인 순수한 화합물 6을 얻었다 (0.193 g, 76%). Rf = 0.54 (EtOAc/hexane = 1/5); 1H NMR (300 MHz, CDCl3) δ 9.89 (1H, s), 7.19 (2H, d, J = 2.4 Hz), 6.98 (1H, t, J = 2.4 Hz), 5.24 (4H, s), 3.73 (4H, q, J = 6.9 Hz), 1.23 (6H, t, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3) δ 191.8, 159.0, 138.6, 111.4, 110.6, 93.5, 64.8, 15.5To the stirred solution of 3,5-dihydroxybenzaldehyde (0.138 g, 1.0 mmol) in anhydrous DMF (7 mL) was added K 2 CO 3 (0.553 g, 4.0 mmol) at room temperature under nitrogen atmosphere. After stirring for 15 minutes, chloromethyl ethyl ether (0.28 mL, 3.0 mmol) was added dropwise and stirred overnight at room temperature. After completion of the reaction, it was diluted with water (10 mL) and extracted with ether (3 x 30 mL). Mixing the organic solvent layer was washed successively with water (3 x 30 mL) and brine (3 x 30 mL), dried over anhydrous Na 2 SO 4, and concentrated in vacuo. The crude compound was purified by column chromatography (EtOAc / hexane = 1/6) to give pure compound 6 (0.193 g, 76%) as a colorless liquid. R f = 0.54 (EtOAc / hexane = 1/5); 1 H NMR (300 MHz, CDCl 3) δ 9.89 (1H, s), 7.19 (2H, d, J = 2.4 Hz), 6.98 (1H, t, J = 2.4 Hz), 5.24 (4H, s), 3.73 (4H, q, J = 6.9 Hz), 1.23 (6H, t, J = 6.9 Hz); 13 C NMR (75 MHz, CDCl 3) δ 191.8, 159.0, 138.6, 111.4, 110.6, 93.5, 64.8, 15.5
1,3-1,3- 비스Bis (( 에톡시메톡시Ethoxymethoxy )-5-) -5- 에티닐벤젠Ethynylbenzene {1,3- {1,3- BisBis (( ethoxymethoxyethoxyMethane )-5-ethynylbenzene} (화합물 7) ) -5-ethynylbenzene} (Compound 7)
(트리메틸실릴)다이아조메탄 (다이에틸에테르에 녹인 2.0 M 용액, 0.75 mL, 1.5 mmol)을 무수 THF (3 mL) 내에서 -78℃로 교반한 용액에 n-BuLi (2.0 M 사이클로헥산 용액, 1.5 ml, 1.5 mmol)를 한 방울씩 가하고 30분간 교반하였다. 여기에 화합물 6 (0.127 g, 0.5 mmol)의 무수 THF (3 ml) 용액을 한 방울씩 가하고 한 시간 동안 교반하였다. 반응 완료 후 NH4Cl 포화 수용액 (1 mL)을 서서히 가하고, 반응 혼합물의 온도를 상온으로 올렸다. 반응 혼합물은 EtOAc (2 x 20 mL)로 추출하였다. 혼합 유기용매층은 식염수 (2 x 15 mL)로 씻고, 무수 Na2SO4로 건조하고 진공농축하였다. 조화합물은 컬럼 크로마토그래피 (EtOAc:Hexane=1:8)로 정제하여 순수한 화합물 7 (0.099 g, 79%)을 얻었다. 1H NMR (300 MHz, CDCl3) δ 6.85 (2H, d, J = 2.4 Hz), 6.75 (1H, t, J = 2.4 Hz), 5.20 (4H, s), 3.73 (4H, q, J = 6.9 Hz), 3.06 (1H, s), 1.25 (6H, t, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3) δ 158.0, 123.3, 113.2, 106.2, 93.1, 83.3, 64.4, 15.2. N- BuLi (2.0 M cyclohexane solution, 2.0 M cyclohexane solution) was added to a solution prepared by stirring (trimethylsilyl) diazomethane (2.0 M solution in diethyl ether, 0.75 mL, 1.5 mmol) in anhydrous THF 1.5 ml, 1.5 mmol) was added dropwise, followed by stirring for 30 minutes. To this was added dropwise a solution of compound 6 (0.127 g, 0.5 mmol) in anhydrous THF (3 ml) and the mixture was stirred for one hour. After completion of the reaction, a saturated aqueous NH 4 Cl solution (1 mL) was slowly added and the temperature of the reaction mixture was raised to room temperature. The reaction mixture was extracted with EtOAc (2 x 20 mL). The combined organic solvent layers were washed with brine (2 x 15 mL), dried over anhydrous Na 2 SO 4 and concentrated in vacuo. The crude compound was purified by column chromatography (EtOAc: Hexane = 1: 8) to give pure compound 7 (0.099 g, 79%). 1 H NMR (300 MHz, CDCl 3) δ 6.85 (2H, d, J = 2.4 Hz), 6.75 (1H, t, J = 2.4 Hz), 5.20 (4H, s), 3.73 (4H, q, J = 6.9 Hz), 3.06 (1H, s), 1.25 (6H, t, J = 6.9 Hz); 13 C NMR (75 MHz, CDCl 3 )? 158.0, 123.3, 113.2, 106.2, 93.1, 83.3, 64.4, 15.2.
2-(3,5-2- (3,5- 비스(에톡시메톡시)페닐Bis (ethoxymethoxy) phenyl )-5,6-) -5,6- 다이메톡시벤조퓨란Dimethoxybenzofuran {2-(3,5-Bis(ethoxymethoxy)phenyl)-5,6-dimethoxybenzofuran} (화합물 8) {2- (3,5-Bis (ethoxymethoxy) phenyl) -5,6-dimethoxybenzofuran} (Compound 8)
화합물 4 (0.072 g, 0.26 mmol), 화합물 7 (0.080 g, 0.32 mmol) 및 트리메틸아민 (0.11 mL, 0.78 mmol)을 밀봉된 튜브 안에 넣고 무수 DMF를 가하였다. Pd(PPh3)4 (0.011 g, 0.02 mmol)와 CuI (0.003 g, 0.02 mmol)를 혼합물에 가하고 2분간 가스를 제거하였다. 반응 혼합물은 80℃에서 15시간 동안 교반하였다. 반응 완료 후 상온으로 식히고 용매는 감압하여 제거하였다. 조화합물은 컬럼 크로마토그래피 (EtOAC/Hexane=1/8)로 정제하여 갈색 액체인 순수한 화합물 8 (0.026 g, 20%)을 얻었다. Rf= 0.28 (EtOAc/hexane=1/3); 1H NMR (300 MHz, CDCl3) δ 7.13 (2H, d, J = 1.8 Hz), 7.11, (1H, s), 7.01 (1H, s), 6.93 (1H, s), 6.72 (1H, t, J = 2.1 Hz), 5.26 (4H, s), 3.94 (3H, s), 3.92 (3H, s), 3.76 (4H, q, J = 6.9 Hz), 1.25 (6H, t, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3) δ 158.5, 154.4, 149.5, 148.0, 146.4, 132.4, 120.8, 105.6, 104.5, 102.0, 95.2, 93.2, 93.1, 64.4, 56.3, 56.2, 15.2 [주: 화합물 8은 PdCl2(dppf).CH2Cl2/anhyd.K3PO4 시스템을 이용하여 스즈키 커플링 반응17b으로 화합물 21과 화합물 23으로부터도 합성할 수 있다.]Compound 4 (0.072 g, 0.26 mmol), compound 7 (0.080 g, 0.32 mmol) and trimethylamine (0.11 mL, 0.78 mmol) were placed in a sealed tube and anhydrous DMF was added. Pd (PPh 3) 4 (0.011 g, 0.02 mmol) and was added CuI (0.003 g, 0.02 mmol) to the mixture for 2 minutes to remove gas. The reaction mixture was stirred at 80 < 0 > C for 15 hours. After completion of the reaction, the reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure. The crude product was purified by column chromatography (EtOAC / Hexane = 1/8) to give pure compound 8 (0.026 g, 20%) as a brown liquid. Rf = 0.28 (EtOAc / hexane = 1/3); 1 H NMR (300 MHz, CDCl 3) δ 7.13 (2H, d, J = 1.8 Hz), 7.11, (1H, s), 7.01 (1H, s), 6.93 (1H, s), 6.72 (1H, t , J = 2.1 Hz), 5.26 (4H, s), 3.94 (3H, s), 3.92 (3H, s), 3.76 (4H, q, J = 6.9 Hz), 1.25 (6H, t, J = 6.9 Hz ); 13 C NMR (75 MHz, CDCl 3) δ 158.5, 154.4, 149.5, 148.0, 146.4, 132.4, 120.8, 105.6, 104.5, 102.0, 95.2, 93.2, 93.1, 64.4, 56.3, 56.2, 15.2 [ Note:
5-(5,6-5- (5,6- 다이메톡시벤조퓨란Dimethoxybenzofuran -2-일)벤젠-1,3-Yl) benzene-1,3- 다이올Diol {5-(5,6- {5- (5,6- DimethoxyDimethoxy benzofuran-2-yl)benzene-1,3-diol} (모라신 F) (화합물 1) benzofuran-2-yl) benzene-1,3-diol} (morazine F) (Compound 1)
화합물 8 (0.025 g, 0.06 mmol)을 무수 메탄올 (2 mL)에 넣고 교반한 용액에 질소 분위기에서 Dowex® 50X2-100 수지 (0.025 g)를 가하였다. 혼합물은 상온에서 12시간 동안 교반하였다. 반응 완료 후 수지를 여과하고 EtOAc (15 mL)로 씻었다. 여과액은 진공농축하였다. 조화합물을 컬럼 크로마토그래피 (EtOAc/hexane=1/1)로 정제하여 백색 고체인 순수한 화합물 1 (0.013 g, 75%)을 얻었다. Rf= 0.32 (EtOAc/hexane=1/1); mp 186-188 ℃; 1H NMR (300 MHz, CD3OD) δ 7.15 (1H, s), 7.08 (1H, s), 6.92 (1H, s), 6.74 (2H, d, J = 1.2 Hz), 6.21 (1H, t, J = 1.2 Hz), 3.88 (3H, s), 3.86 (3H, s); 13C NMR (75 MHz, CD3OD) δ 158.7, 155.4, 149.7, 148.4, 146.9, 132.5, 121.5, 103.0, 102.7, 102.3, 101.3, 95.4, 55.9, 55.7; EI-MS m/z 286 (M+, base), 271, 257.Compound was added to 8 (0.025 g, 0.06 mmol) in anhydrous methanol (2 mL) Dowex ® 50X2-100 resin (0.025 g) in a nitrogen atmosphere to a stirred solution into a. The mixture was stirred at room temperature for 12 hours. After completion of the reaction, the resin was filtered and washed with EtOAc (15 mL). The filtrate was concentrated in vacuo. The crude compound was purified by column chromatography (EtOAc / hexane = 1/1) to obtain pure compound 1 (0.013 g, 75%) which was a white solid. Rf = 0.32 (EtOAc / hexane = 1/1); mp 186-188 [deg.] C; 1 H NMR (300 MHz, CD 3 OD) δ 7.15 (1H, s), 7.08 (1H, s), 6.92 (1H, s), 6.74 (2H, d, J = 1.2 Hz), 6.21 (1H, t , J = 1.2 Hz), 3.88 (3H, s), 3.86 (3H, s); 13 C NMR (75 MHz, CD 3 OD)? 158.7, 155.4, 149.7, 148.4, 146.9, 132.5, 121.5, 103.0, 102.7, 102.3, 101.3, 95.4, 55.9, 55.7; EI-MS m / z 286 (M < + > , base), 271, 257.
1-(3,5-1- (3,5- 비스((Bis (( terttert -부틸다이메틸실릴)옥시)페닐- butyl dimethylsilyl) oxy) phenyl )) 에타논Ethanone {1-(3,5-Bis(( {1- (3,5-Bis (( terttert -butyldimethylsilyl)oxy)phenyl)ethanone} (화합물 10)-butyldimethylsilyl) oxy) phenyl) ethanone} (Compound 10)
3,5-다이하이드록시아세토페논 (0.076 g, 0.5 mmol), TBSCl (0.226 g, 1.5 mmol) 및 이미다졸 (0.17 g, 2.5 mmol)을 무수 DMF (6 mL) 내에서 4.5시간 동안 반응시킨 후 화합물 3 합성방법과 같은 방법으로 무색 액체인 화합물 10을 합성하였다. 1H NMR (300MHz, CDCl3) δ 7.01 (2H, d, J = 2.1 Hz), 6.51 (1H, t, J = 2.1 Hz), 2.53 (3H, s), 0.98 (18H, s), 0.21 (12H, s); 13C NMR (75MHz, CDCl3) δ 197.7, 156.8, 139.2, 117.0, 113.5, 27.1, 26.0, 18.6, -4.0.(0.026 g, 0.5 mmol), TBSCl (0.226 g, 1.5 mmol) and imidazole (0.17 g, 2.5 mmol) were reacted in anhydrous DMF (6 mL) for 4.5
1-(3,5-1- (3,5- 비스((Bis (( terttert -부틸다이메틸실릴)옥시)페닐- butyl dimethylsilyl) oxy) phenyl )-2-)-2- 브로모에타논Bromoethanone {1-(3,5-Bis(( {1- (3,5-Bis (( terttert -butyldimethylsilyl)oxy)phenyl)-2-bromoethanone} (화합물 11)-butyldimethylsilyl) oxy) phenyl) -2-bromoethanone} (Compound 11)
치환된 아세토페논 화합물 10 (0.19 g, 0.5 mmol)을 EtOAc (5 mL)에서 교반한 용액에 브롬화 구리(Ⅱ) (0.279 g, 1.25 mmol)를 상온에서 가하고, 혼합물은 2.5시간 동안 환류하였다. 상온으로 식힌 후 혼합물은 Celite® 패드로 여과하고 EtOAc (10 mL)로 씻었다. 여과액은 진공농축하였다. 조화합물을 짧은 컬럼 (EtOAc/hexane=1/15)으로 정제하여 연황색 액체인 순수한 화합물 11 (0.2 g, 87%)을 얻었다. Rf= 0.64 (EtOAc/Hexane = 1/10); 1H NMR (300 MHz, CDCl3) δ 7.12 (2H, s), 6.56 (1H, s), 4.37 (2H, s), 0.98 (18H, s), 0.22 (12H, s); 13C NMR (75 MHz, CDCl3) δ 189.1, 160.8, 133.8, 114.2, 110.9, 34.7, 25.3, 14.3, -4.20. Copper (II) bromide (0.279 g, 1.25 mmol) was added at room temperature to a solution of the substituted acetophenone compound 10 (0.19 g, 0.5 mmol) in EtOAc (5 mL) and the mixture was refluxed for 2.5 hours. After cooling to room temperature, the mixture was filtered through a pad of Celite® and washed with EtOAc (10 mL). The filtrate was concentrated in vacuo. The crude compound was purified by short column (EtOAc / hexane = 1/15) to give
((5-(5,6-다이메톡시벤조퓨란-2-일)((5- (5,6-dimethoxybenzofuran-2-yl) -1,3--1,3- 페닐렌Phenylene )) 비스(옥시))비스(Bis (oxy) bis terttert -부-part 틸다이메틸실란) {((5-(5,6-Tiladimethylsilane) {((5- (5,6- DimethoxybenzofuranDimethoxybenzofuran -2--2- ylyl )-1,3-) -1,3- phenylenehenylene )bis (oxy))bis() bis (oxy)) bis ( terttert -butyldimethylsilane)} (화합물 12)-butyldimethylsilane)} (Compound 12)
화합물 2 (0.068 g, 0.44 mmol), α-브로모아세토페논 화합물 11 (0.2 g, 0.44 mmol) 및 중성 산화알루미늄 (0.156 g, 1.53 mmol)의 혼합물을 48시간 동안 자일렌 (3 mL) 내에서 환류하였다. 반응물은 Celite® 패드로 여과하고 증발시켰다. 잔여물을 실리카젤 상에서 에틸 아세테이트/헥산을 용출액으로 이용하여 컬럼 크로마토그래피로 정제하여 갈색 액체인 해당 벤조퓨란 (0.018 mg, 8%)을 얻었다. Rf= 0.22 (EtOAc/hexane=1/3); 1H NMR (300 MHz, CDCl3) δ 7.09 (1H, s), 6.98 (1H, s), 6.89 (2H, d, J = 1.8 Hz), 6.85 (1H, s), 6.28 (1H, t, J = 1.8 Hz), 3.94 (3H, s), 3.92 (3H, s), 1.00 (18H, s), 0.23 (12H, s); 13C NMR (75 MHz, CDCl3) δ 157.0, 154.9, 149.8, 148.2, 146.7, 132.5, 121.2, 112.1, 109.8, 102.3, 102.0, 95.5, 56.6, 56.5, 26.1, 18.6, -3.9.A mixture of compound 2 (0.068 g, 0.44 mmol), alpha -bromoacetophenone compound 11 (0.2 g, 0.44 mmol) and neutral aluminum oxide (0.156 g, 1.53 mmol) was added in xylene (3 mL) Lt; / RTI > The reaction was filtered through a Celite pad and evaporated. The residue was purified by column chromatography on silica gel using ethyl acetate / hexane as eluant to afford the corresponding benzofuran (0.018 mg, 8%) as a brown liquid. Rf = 0.22 (EtOAc / hexane = 1/3); 1 H NMR (300 MHz, CDCl 3) δ 7.09 (1H, s), 6.98 (1H, s), 6.89 (2H, d, J = 1.8 Hz), 6.85 (1H, s), 6.28 (1H, t, J = 1.8 Hz), 3.94 (3H, s), 3.92 (3H, s), 1.00 (18H, s), 0.23 (12H, s); 13 C NMR (75 MHz, CDCl 3 ) 隆 157.0, 154.9, 149.8, 148.2, 146.7, 132.5, 121.2, 112.1, 109.8, 102.3, 102.0, 95.5, 56.6, 56.5, 26.1, 18.6,
5-(5,6-5- (5,6- 다이메톡시벤조퓨란Dimethoxybenzofuran -2-일)벤젠-1,3-Yl) benzene-1,3- 다이올Diol {5-(5,6-Dimethoxybenzofuran-2-yl)benzene-1,3-diol} ( {5- (5,6-Dimethoxybenzofuran-2-yl) benzene-1,3-diol} ( 모라신Mora F) (화합물 1) F) (Compound 1)
TBS-보호기화된 벤조퓨란 화합물 12 (0.015 g, 0.029 mmol)를 무수 THF에 넣고 교반한 용액에 1.0 M TBAF (0.07 mL, 0.07 mmol)를 가하고 상온에서 네 시간 동안 교반하였다. 반응 완료 후 용매는 진공으로 제거하였다. 조화합물을 컬럼 크로마토그래피 (EtOAc/hexane=1/1)로 정제하여 백색 고체인 순수한 화합물 1 (0.008 g, 90%)을 얻었다.1.0 M TBAF (0.07 mL, 0.07 mmol) was added to TBS-protected benzofuran compound 12 (0.015 g, 0.029 mmol) in anhydrous THF and stirred at room temperature for 4 hours. After completion of the reaction, the solvent was removed in vacuo. The crude compound was purified by column chromatography (EtOAc / hexane = 1/1) to obtain pure compound 1 (0.008 g, 90%) which was a white solid.
3,5-3,5- 비스(알릴옥시)벤조산Bis (allyloxy) benzoic acid {3,5- {3,5- Bis(allyloxy)benzoicBis (allyloxy) benzoic acid} (화합물 acid} (Compound 14)14)
3,5-다이하이드록시벤조산 (화합물 13) (0.2 g, 1.298 mmol)과 K2CO3 (0.897 g, 6.489 mmol)를 무수 DMF (8 mL)에서 교반한 현탁액에 알릴 브로마이드 (0.34 mL, 3.793 mmol)를 질소 분위기에서 상온으로 서서히 가하였다. 반응 혼합물은 세 시간 동안 교반하였다. 반응 완료 후 Celite® 패드로 여과하고 에테르 (30 mL)로 씻었다. 여과액은 물 (3 x 15 mL)과 식염수 (3 x 15 mL)로 씻고, 무수 Na2SO4로 건조하여 진공농축하였다. 조화합물을 컬럼 크로마토그래피 (EtOAc/hexane=1/2)로 정제하여 무색 액체인 알릴 3,5-비스(알릴옥시)벤조에이트 (0.327 g, 92%)를 얻었다. Rf=0.80 (EtOAc/hexane=1/2); 1H NMR (300 MHz, CDCl3) δ 7.20 (2H, d, J = 2.4 Hz), 6.68 (1H, t, J = 2.4 Hz), 6.02 (3H, m), 5.40 (3H, dd, J = 17.1, 1.5 Hz), 5.28 (3H, dd, J = 10.2, 1.5 Hz), 4.80 (2H, dt, J = 5.4, 1.5 Hz), 4.54 (4H, dt, J = 4.8, 1.5 Hz); 13C NMR (75 MHz, CDCl3) δ 166.0, 159.7, 133.0, 132.3, 132.1, 118.4, 118.1 108.5, 107.3, 69.4, 66.0. 상기 에스테르 (0.175 g, 0.638 mmol)를 메탄올 (5 mL)에 넣고 교반한 용액에 1.0 N NaOH (1.91 mL)를 가하고 두 시간 동안 환류하였다. 상온으로 식히고, 용매는 감압하여 제거하였다. 1N HCl로 대략의 pH를 2로 맞추고, EtOAc (2 x 25 mL)로 추출하였다. 혼합 유기용매층은 식염수 (2 x 30 mL)로 세척하고, 무수 Na2SO4로 건조한 후 진공농축하였다. 정제되지 않은 백색 고체인 산 화합물14 (0.127 g, 85%)를 얻었고, 더이상 정제하지 않고 다음 단계에서 사용하였다. 녹는점 64-66 ℃; 1H NMR (300 MHz, CDCl3) δ 7.28 (2H, d, J = 2.4 Hz), 6.70 (1H, t, J = 2.4 Hz), 6.06 (2H, m), 5.44 (2H, dd, J = 17.1, 1.5 Hz), 5.32 (2H, dd, J = 10.5, 1.5 Hz), 4.58 (4H, dt, J = 5.5, 1.5 Hz); 13C NMR (75 MHz, CDCl3) δ 172.0, 159.6, 132.7, 131.0, 118.1, 108.6, 108.0, 69.1To a suspension of 3,5-dihydroxybenzoic acid (Compound 13 ) (0.2 g, 1.298 mmol) and K 2 CO 3 (0.897 g, 6.489 mmol) in anhydrous DMF (8 mL) was added allyl bromide (0.34 mL, 3.793 mmol) was gradually added to the room temperature in a nitrogen atmosphere. The reaction mixture was stirred for three hours. After completion of the reaction, the reaction mixture was filtered through a Celite pad and washed with ether (30 mL). The filtrate was washed with water (3 x 15 mL) and brine (3 x 15 mL), dried over anhydrous Na 2 SO 4 and concentrated in vacuo. The crude compound was purified by column chromatography (EtOAc / hexane = 1/2) to obtain
2-(2-( 하이드록시메틸Hydroxymethyl )-4,5-) -4,5- 다이메톡시페놀Dimethoxyphenol {2-( {2-( HydroxymethylHydroxymethyl )-4,5-dimethoxyphenol} (화합물 17)) -4,5-dimethoxyphenol} (Compound 17)
2-하이드록시-4,5-다이메톡시벤즈알데하이드 (화합물 16) (0.1 g, 0.54 mmol)을 에탄올 (3 mL)에 넣고 교반한 용액에 수소화 붕소나트륨 (sodium borohydride) (0.021 g, 0.55 mmol)을 0℃에서 가하였다. 반응 혼합물은 상온에서 한 시간 동안 교반하였다. 용매를 제거한 후 수용성 1N HCl 용액 (4 mL)을 잔여물에 가하고 CH2Cl2 (2 x 20 mL)로 추출하였다. 유기용매층은 무수 Na2SO4로 건조하고 여과하였다. 여과액을 농축하여 맑은 액체인 알콜 화합물 17 (0.09 g, 90%)을 얻었다. Rf= 0.20 (EtOAc/hexane=1/2); 1H NMR (300 MHz, CDCl3) δ 6.74 (1H, s), 5.93 (1H, s), 5.82 (1H, br s), 4.58 (2H, br d, J = 4.5 Hz), 4.15 (1H, br s), 3.86 (3H, s), 3.83 (3H, s); 13C NMR (75 MHz, CDCl3) δ 159.8, 159.0, 147.9, 129.4, 108.2, 107.3, 60.0, 59.0, 56.8To a stirred solution of 2-hydroxy-4,5-dimethoxybenzaldehyde (Compound 16) (0.1 g, 0.54 mmol) in ethanol (3 mL) was added sodium borohydride (0.021 g, 0.55 mmol ) At 0 < 0 > C. The reaction mixture was stirred at room temperature for one hour. After removal of the solvent, aqueous 1N HCl solution (4 mL) was added to the residue and extracted with CH 2 Cl 2 (2 x 20 mL). The organic solvent layer was dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated to obtain a clear liquid alcohol compound 17 (0.09 g, 90%). Rf = 0.20 (EtOAc / hexane = 1/2); 1 H NMR (300 MHz, CDCl 3) δ 6.74 (1H, s), 5.93 (1H, s), 5.82 (1H, br s), 4.58 (2H, br d, J = 4.5 Hz), 4.15 (1H, br s), 3.86 (3H, s), 3.83 (3H, s); 13 C NMR (75 MHz, CDCl 3 )? 159.8, 159.0, 147.9, 129.4, 108.2, 107.3, 60.0, 59.0, 56.8
2-((2-(( 브로모트리페닐포스포라닐Bromotriphenylphosphoranyl )) 메틸methyl )-4,5-) -4,5- 다이메톡시페놀Dimethoxyphenol {2-((Bromotriphenylphosphoranyl)methyl)-4,5-dimethoxyphenol} (화합물 18) {2 - ((Bromotriphenylphosphoranyl) methyl) -4,5-dimethoxyphenol} (Compound 18)
화합물 17 (0.076 g, 0.41 mmol)을 아세토나이트릴 (3 mL)에 넣고 교반한 용액에 트리페닐포스파인 하이드로브로마이드 (triphenylphosphine hydrobromide) (0.145 g, 0.41 mmol)를 가하고, 혼합물을 한 시간 동안 환류하였다. 반응 완료 후, 상온으로 식히고 여과한 후 아세토나이트릴(8 mL)로 씻고 건조하여 고체 화합물 18 (0.2 g, 95%)을 얻었다. 1H NMR (300 MHz, CDCl3) δ 7.78-7.39 (15H, m), 6.89 (1H, s), 6.37 (1H, s), 5.39 (1H, s), 4.49 (2H, d, J = 12.0 Hz), 3.71 (3H, s), 3.68 (3H, s). Triphenylphosphine hydrobromide (0.145 g, 0.41 mmol) was added to a stirred solution of compound 17 (0.076 g, 0.41 mmol) in acetonitrile (3 mL) and the mixture was refluxed for one hour . After completion of the reaction, the reaction mixture was cooled to room temperature, filtered, washed with acetonitrile (8 mL) and dried to obtain solid compound 18 (0.2 g, 95%). 1 H NMR (300 MHz, CDCl 3) δ 7.78-7.39 (15H, m), 6.89 (1H, s), 6.37 (1H, s), 5.39 (1H, s), 4.49 (2H, d, J = 12.0 Hz), 3.71 (3H, s), 3.68 (3H, s).
2-(3,5-2- (3,5- 비스(알릴옥시)페닐Bis (allyloxy) phenyl )-5,6-) -5,6- 다이메톡시벤조퓨란Dimethoxybenzofuran {2-(3,5-Bis(allyloxy)phenyl)-5,6-dimethoxybenzofuran} (화합물 19) {2- (3,5-Bis (allyloxy) phenyl) -5,6-dimethoxybenzofuran} (Compound 19)
티오닐 클로라이드 (0.07 mL, 0.96 mmol)를 상기 산 화합물 14 (0.150 g, 0.64 mmol)에 가하고 두 시간 동안 환류하였다. 상온으로 식히고 과량의 티오닐 클로라이드를 감압하여 제거하고 염화 산 (acid chloride) 화합물을 얻었다. 1H NMR (300 MHz, CDCl3) δ 7.24 (2H, d, J = 2.1 Hz), 6.77 (1H, t, J = 2.1 Hz), 6.03 (2H, m), 5.42 (2H, dd, J = 17.1, 0.9 Hz), 5.31 (2H, dd, J = 10.8, 0.9 Hz), 4.56 (4H, d, J = 5.4 Hz) 13C NMR (75 MHz, CDCl3) δ 167.9, 159.5, 134.7, 132.2, 118.2, 109.8, 109.1, 69.2. 상기 염화 산에 위티그 염 (Wittig salt) 화합물 18 (0.3 g, 0.58 mmol), 트리메틸아민 (0.25 mL)과 톨루엔 (10 mL)을 가하고 세 시간 동안 환류하였다. 상온으로 식히고 침전물은 여과하고 EtOAc (10 mL)로 세척하였다. 여과액은 진공농축하였다. 조화합물을 컬럼 크로마토그래피 (EtOAc/hexane=1/7)로 정제하여 맑은 액체인 순수한 벤조퓨란 화합물 19 (0.033 g, 15%)를 얻었다. Rf= 0.28 (EtOAc/hexane=1/4); 1H NMR (300 MHz, CDCl3) δ 7.07 (1H, s), 6.99 (1H, s), 6.96 (2H, d, J = 2.1 Hz), 6.88 (1H, s), 6.46 (1H, t, J = 2.4 Hz), 6.07 (2H, m), 5.44 (2H, dd, J = 17.1, 1.2 Hz), 5.31 (2H, dd, J = 10.2, 1.2 Hz), 4.58 (4H, dt, J = 5.4 Hz), 3.94 (3H, s), 3.93 (3H, s); 13C NMR (75 MHz, CDCl3) δ 159.7, 154.5, 149.3, 147.3, 146.3, 132.8, 132.2, 120.7, 117.6, 103.2, 101.9, 101.7, 101.5, 95.0, 68.8, 56.2, 56.1Thionyl chloride (0.07 mL, 0.96 mmol) was added to the above acid compound 14 (0.150 g, 0.64 mmol) and refluxed for two hours. The mixture was cooled to room temperature and excess thionyl chloride was removed under reduced pressure to obtain an acid chloride compound. 1 H NMR (300 MHz, CDCl 3) δ 7.24 (2H, d, J = 2.1 Hz), 6.77 (1H, t, J = 2.1 Hz), 6.03 (2H, m), 5.42 (2H, dd, J = 17.1, 0.9 Hz), 5.31 ( 2H, dd, J = 10.8, 0.9 Hz), 4.56 (4H, d, J = 5.4 Hz) 13 C NMR (75 MHz, CDCl 3) δ 167.9, 159.5, 134.7, 132.2, 118.2, 109.8, 109.1, 69.2. Wittig salt 18 (0.3 g, 0.58 mmol), trimethylamine (0.25 mL) and toluene (10 mL) were added to the hydrochloric acid and refluxed for three hours. It was cooled to room temperature and the precipitate was filtered and washed with EtOAc (10 mL). The filtrate was concentrated in vacuo. The crude compound was purified by column chromatography (EtOAc / hexane = 1/7) to obtain pure benzofuran compound 19 (0.033 g, 15%) as a clear liquid. Rf = 0.28 (EtOAc / hexane = 1/4); 1 H NMR (300 MHz, CDCl 3) δ 7.07 (1H, s), 6.99 (1H, s), 6.96 (2H, d, J = 2.1 Hz), 6.88 (1H, s), 6.46 (1H, t, J = 2.4 Hz), 6.07 ( 2H, m), 5.44 (2H, dd, J = 17.1, 1.2 Hz), 5.31 (2H, dd, J = 10.2, 1.2 Hz), 4.58 (4H, dt, J = 5.4 Hz), 3.94 (3H, s), 3.93 (3H, s); 13 C NMR (75 MHz, CDCl 3 )? 159.7, 154.5, 149.3, 147.3, 146.3, 132.8, 132.2, 120.7, 117.6, 103.2, 101.9, 101.7, 101.5, 95.0, 68.8, 56.2, 56.1
5-(5,6-5- (5,6- 다이메톡시벤조퓨란Dimethoxybenzofuran -2-일)벤젠-1,3-Yl) benzene-1,3- 다이올Diol {5-(5,6-Dimethoxybenzofuran-2-yl)benzene-1,3-diol} ( {5- (5,6-Dimethoxybenzofuran-2-yl) benzene-1,3-diol} ( 모라신Mora F) (화합물 1) F) (Compound 1)
Pd(PPh3)3 (0.002 g, 2 mmol%)를 화합물 19 (0.025 g, 0.068 mmol)와 K2CO3 (0.056 g 0.408 mmol)를 메탄올 (3 mL)에 넣고 교반한 현탁액에 질소 분위기에서 가했다. 혼합물은 60℃에서 세 시간 동안 교반하였다. 상온으로 식힌 ㅎ후 용매는 감압하여 제거하였다. 조화합물은 1N HCl로 중화하고 CH2Cl2 (2 x 15 mL)로 추출하였다. 혼합 유기용매층은 식염수 (2 x 10 mL)로 씻고, 무수 Na2SO4 하에서 건조하고 진공농축하였다. 조화합물을 컬럼 크로마토그래피 (EtOAc/hexane=1/2)로 정제하여 백색 고체인 순수한 벤조퓨란 화합물 1 (0.017 g, 86%)을 얻었다.To a suspension of compound 19 (0.025 g, 0.068 mmol) and K 2 CO 3 (0.056 g 0.408 mmol) in methanol (3 mL) was added Pd (PPh 3 ) 3 (0.002 g, 2 mmol%) in a nitrogen atmosphere He said. The mixture was stirred at 60 < 0 > C for three hours. The supernatant cooled at room temperature was removed under reduced pressure. The crude compound was neutralized with IN HCl and extracted with CH 2 Cl 2 (2 x 15 mL). Mixing the organic solvent layer is washed with brine (2 x 10 mL), dried under anhydrous Na 2 SO 4, and concentrated in vacuo. The crude compound was purified by column chromatography (EtOAc / hexane = 1/2) to obtain
2-(2,2-2- (2,2- 다이브로모비닐Dive Vinyl Vinyl )-4,5-) -4,5- 다이메톡시페놀Dimethoxyphenol {2-(2,2- {2- (2,2- DibromovinylDibromovinyl )-4,5-dimethoxyphenol} (화합물 20)) -4,5-dimethoxyphenol} (Compound 20)
화합물 20은 참고문헌 17b에 기재된 방법대로 화합물 16으로부터 제조하였다.17b 수율: 49%; 갈색 액체; Rf= 0.23 (EtOAc/hexane=1/1); 1H NMR (300 MHz, CDCl3) δ 7.51 (1H, s), 7.10 (1H, s), 6.43 (1H, s), 4.80 (1H, s), 3.87 (3H, s), 3.86 (3H, s); 13C NMR (75 MHz, CDCl3) δ 150.4, 147.3, 143.0, 132.0, 113.8, 111.5, 100.6, 90.7, 56.7
2-2- 브로모Bromo -5,6--5,6- 다이메톡시벤조퓨란Dimethoxybenzofuran (2- (2- BromoBromo -5,6--5,6- dimethoxybenzofurandimethoxybenzofuran ) (화합물 21)) (Compound 21)
화합물 21은 참고문헌 17b에 기재된 방법대로 화합물 20으로부터 제조하였다.17b 수율: 81%; 갈색 액체; Rf= 0.64 (EtOAc/hexane=1/1); 1H NMR (300 MHz, CDCl3) δ 6.99 (1H, s), 6.92 (1H, s), 6.60 (1H, s), 3.90 (6H, s); 13C NMR (75 MHz, CDCl3) δ 150.3, 150.3, 146.7, 125.2, 120.5, 108.0, 101.2, 95.0, 56.4, 56.2
2-(3,5-2- (3,5- 비스(에톡시메톡시)페닐Bis (ethoxymethoxy) phenyl )-4,4,5,5-) -4,4,5,5- 테트라메틸Tetramethyl -1,3,2--1,3,2- 다이옥사보롤란Dioxabololan {2-(3,5- {2- (3,5- Bis(ethoxymethoxy)phenylBis (ethoxymethoxy) phenyl )-4,4,5,5-) -4,4,5,5- tetramethyltetramethyl -1,3,2-dioxaborolane} (화합물 23)-1,3,2-dioxaborolane} (Compound 23)
화합물 23은 참고문헌 17b에 기재된 방법대로 화합물 22로부터 제조하였다.17b 1H NMR (300MHz, CDCl3) δ 7.08 (2H, d, J = 2.4 Hz), 6.82 (1H, t, J = 2.4 Hz), 5.21 (4H, s), 3.72 (4H, q, J = 6.9 Hz), 1.32 (12H, s) 1.22 (6H, t, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3) δ 157.8, 115.3, 108.2, 93.1, 83.8, 64.3, 24.9, 15.2.
Claims (3)
(나) 상기 2-(3,5-비스(알릴옥시)페닐)-5,6-다이메톡시벤조퓨란에 K2CO3 및 촉매 Pd(PPh3)4를 가하여 모라신 F를 얻는 단계;를 포함하는 모라신 F 합성방법.
<화학식 18>
<화학식 15>
<화학식 19>
(A) 2 - ((Bromotriphenylphosphoranyl) methyl) -4,5-dimethoxyphenol represented by the formula (18) and {2 - ((Bromotriphenylphosphoranyl) methyl) (Allyloxy) phenyl) -5,6-dimethoxybenzoyl chloride represented by the formula 19 is obtained by an intramolecular Wittig reaction between 3,5-bis (allyloxy) benzoyl chloride represented by the formula {2- (3,5-Bis (allyloxy) phenyl) -5,6-dimethoxybenzofuran}; And
(B) adding K 2 CO 3 and catalyst Pd (PPh 3 ) 4 to the 2- (3,5-bis (allyloxy) phenyl) -5,6-dimethoxybenzofuran to obtain morasin F; ≪ / RTI >
≪ Formula 18 >
≪ Formula 15 >
(19)
상기 3,5-비스(알릴옥시)벤조일클로라이드는 3,5-다이하이드록시벤조산을 알릴 보호기화-에스테르화, 에스테르 가수분해 및 염소화의 순서에 따라 반응시켜 제조한 것임을 특징으로 하는 모라신 F 합성방법.The method according to claim 1,
Wherein the 3,5-bis (allyloxy) benzoyl chloride is prepared by reacting 3,5-dihydroxybenzoic acid with allyl protecting gas-esterification, ester hydrolysis and chlorination in the order of morphine F synthesis Way.
상기 2-((브로모트리페닐포스포라닐)메틸)-4,5-다이메톡시페놀은
(ㄱ) 화학식 16으로 표시되는 2-하이드록시-4,5-다이메톡시벤즈알데하이드를 환원시켜 화학식 17로 표시되는 2-(하이드록시메틸)-4,5-다이메톡시페놀 {2-(Hydroxymethyl)-4,5-dimethoxyphenol}을 얻는 단계; 및
(ㄴ) 상기 2-(하이드록시메틸)-4,5-다이메톡시페놀을 PPh3·HBr (triphenylphosphinehydrobromide)와 반응시켜 2-((브로모트리페닐포스포라닐)메틸)-4,5-다이메톡시페놀을 얻는 단계;를 포함하는 모라신 F 합성방법.
<화학식 16>
<화학식 17>
The method according to claim 1,
The 2 - ((bromotriphenylphosphoranyl) methyl) -4,5-dimethoxyphenol is a
(A) Reduction of 2-hydroxy-4,5-dimethoxybenzaldehyde represented by the formula (16) to obtain 2- (hydroxymethyl) -4,5-dimethoxyphenol {2- Hydroxymethyl) -4,5-dimethoxyphenol}; And
(B) reacting the 2- (hydroxymethyl) -4,5-dimethoxyphenol with PPh 3揃 HBr (triphenylphosphinehydrobromide) to obtain 2 - ((bromotriphenylphosphoranyl) methyl) To obtain a dimethoxy phenol.
≪ Formula 16 >
≪ Formula 17 >
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160035653A KR101729239B1 (en) | 2016-03-25 | 2016-03-25 | Synthetic method for moracin F using intramolecular Wittig reaction |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160035653A KR101729239B1 (en) | 2016-03-25 | 2016-03-25 | Synthetic method for moracin F using intramolecular Wittig reaction |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101729239B1 true KR101729239B1 (en) | 2017-04-21 |
Family
ID=58705396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160035653A KR101729239B1 (en) | 2016-03-25 | 2016-03-25 | Synthetic method for moracin F using intramolecular Wittig reaction |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101729239B1 (en) |
-
2016
- 2016-03-25 KR KR1020160035653A patent/KR101729239B1/en active IP Right Grant
Non-Patent Citations (2)
Title |
---|
논문1(한림대학교,2015)* |
논문2(J. CHEM. SOC.,1998) |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yin et al. | Synthesis of functionalized 2-aryl-4-(indol-3-yl)-4 H-chromenes via iodine-catalyzed domino Michael addition–intramolecular cyclization reaction | |
JP5208239B2 (en) | Novel production method of anticancer active tricyclic compounds by alkyne coupling | |
JP6807396B2 (en) | Method for preparing high-purity cyclohexenone long-chain alcohol | |
EP2931708A2 (en) | Cyclopropylboronic compounds, method for preparing same and use thereof | |
Wang et al. | Stereoselective total synthesis of cochliomycin A | |
Dumitrescu et al. | Synthesis and cytotoxic activity of fluorinated analogues of Goniothalamus lactones. Impact of fluorine on oxidative processes | |
Sivaraman et al. | A protecting group-free divergent synthesis of natural benzofurans via one-pot synthesis of 2-bromo-6-hydroxybenzofurans | |
KR101729239B1 (en) | Synthetic method for moracin F using intramolecular Wittig reaction | |
Yadav et al. | Stereoselective and facile total synthesis of (+)-goniodiol, a styryllactone from carbohydrates | |
KR101739728B1 (en) | Synthetic method for moracin F using Sonogashira coupling reaction | |
RU2745062C2 (en) | Producing method of long-chain alcohol of high purity cyclohexenone | |
KR101778964B1 (en) | Synthetic method for moracin F using Suzuki coupling reaction | |
Bensulong et al. | DBU-mediated regioselective intramolecular cyclization/dehydration of ortho diketo phenoxyethers: a synthesis of 2, 3-substituted γ-benzopyranones | |
Fisyuk et al. | Synthesis of 4 H-thieno [3, 2-c] chromenes by intramolecular arylation of 4-aryloxy-methyl-5-iodothiophene-2-carbaldehydes | |
Yun et al. | Diversity Oriented Synthesis of Natural 2‐Arylbenzofuran, Moracin F | |
KR101682908B1 (en) | Synthetic method for Mulberrofuran B and L | |
KR20170052830A (en) | Synthetic method for rugchalcone A, B and their derivatives and their anti-inflammatory use | |
Kobayashi et al. | Synthesis of 3‐(ω‐Hydroxyalkoxy) isobenzofuran‐1 (3H)‐ones by Trifluoroacetic Acid‐Mediated Lactonization of tert‐Butyl 2‐(1, 3‐Dioxol‐2‐yl)‐or 2‐(1, 3‐Dioxan‐2‐yl) benzoates | |
CN107001209B (en) | Formation of chromans based on intermolecular reactions of alkynes with dimethylfurans in the presence of gold (I) complexes | |
JP2005504019A (en) | Method for preparing isocoumarin | |
Piemontese et al. | Convenient synthesis of some 3-phenyl-1-benzofuran-2-carboxylic acid derivatives as new potential inhibitors of CLC-Kb channels | |
KR101651226B1 (en) | A process for the preparation puerariafuran | |
Zhang et al. | Synthesis of an Antitumoral Diarylheptanoid Containing 1, 3‐Diol Functionality | |
Toyota et al. | Unexpected formation of 4, 7-dihalobenzo [b] thiophenes using Ohira-Bestmann reagent and reactivity of the halogen-substituted benzo [b] thiophenes in Suzuki-Miyaura coupling with phenylboronic acid | |
Azizian et al. | Highly functionalized dihydrofuran derivatives: Synthesis by diastereoselective intramolecular Wittig reaction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |